First-Line Treatment for Newly Diagnosed Lennox-Gastaut Syndrome
When Lennox-Gastaut syndrome (LGS) is newly diagnosed or clinically suspected, selecting an appropriate first-line therapy is the immediate priority. The evidence-based approach involves a specific monotherapy with important patient-specific prescribing considerations.
This protocol applies at initial presentation of LGS. A key patient characteristic — reproductive status — directly determines whether the recommended first-line agent is appropriate or whether an alternative must be considered.
Treatment approach — partial overview
Sodium valproate-based monotherapy is the recommended first-line option for newly diagnosed LGS, with mandatory prescribing restrictions that apply to specific patient groups. The complete eligibility criteria, contraindications, and the full management algorithm are available in the structured protocol.
References
DOI: 10.1002/epi4.13075
- For a patient presenting with newly diagnosed LGS or suspected LGS, the recommended first-line treatment is VPA (Figure 1).
- VPA should generally not be used in women of childbearing potential, due to its high teratogenic potential, unless no suitable alternatives exist, and effective contraception is used.
View source ↗